Sanofi is at the forefront of a new era in therapeutics with their NANOBODY® Technology Platform. These tiny, modular antibodies, derived from "heavy-chain-only" peptides found in llamas and other camelids, are creating a buzz in the industry. This revolutionary platform enables the creation of new therapeutics and the refinement of existing treatments.

NANOBODY® molecules, a tenth the size of conventional antibodies, have the ability to bind to multiple targets simultaneously, making them an essential tool in drug discovery. Sanofi's large-scale manufacturing capacity coupled with NANOBODY® molecules and other cutting-edge technologies empower their teams to develop the medicines of tomorrow. With a patent portfolio of over 500 patents, Sanofi Ablynx is leading the way in the development, optimization, and clinical use of NANOBODY® molecules.

Through their innovative products and wide-ranging capabilities, Sanofi is revolutionizing the field of therapeutics and setting new standards for the treatment of various diseases and conditions